(HealthDay News) — For patients with early-stage breast cancer, hospitalization rates vary with different chemotherapy regimens, according to a study published online May 27 in the Journal of Clinical Oncology.

Carlos H. Barcenas, MD, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues compared the risk of hospitalization among patients with early-stage breast cancer. Data were collected for 3,567 patients >65 years from the Surveillance, Epidemiology, and End Results/Texas Cancer Registry-Medicare database and for 9,327 patients <65 years from the MarketScan database. Patients were classified according to treatment regimens: docetaxel (T) and cyclophosphamide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P.

The researchers found that the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC) among patients <65 years, with significantly higher rates of hospitalization for those who received TAC and AC + T vs. TC. The hospitalization rates ranged from 12.7% (TC) to 24.2% (TAC) among patients >65 years, with higher rates of hospitalization for patients who received TAC, AC + T, AC, or AC + weekly P vs. TC.

“Results may be affected by selection biases where less aggressive regimens are offered to frailer patients,” write the authors.

Two authors disclosed financial ties to the medical technology industry.

Full Text (subscription or payment may be required)